INTRODUCTION
============

Hypertrophic osteoarthropathy (HOA) is a clinical syndrome characterized by proliferative periostitis of the long bone, arthritis with non-inflammatory synovial fluid mostly affecting the knees and ankles, and digital clubbing \[[@R1]\]. HOA is commonly associated with intra-thoracic malignancies, and primary lung cancer accounts for about 80% of patients \[[@R2],[@R3]\]. A recent large study involving 6151 lung cancer patients found the incidence of HOA to be 1.87%, of which 83% patients had non-small cell carcinoma \[[@R4]\].

Antinuclear antibodies (ANA) (titer 1:80) frequency is increased by eight-fold in malignancies compared to age matched controls and was reported to be 27% in lung carcinoma \[[@R5]\]. Although anti-double stranded DNA (anti-dsDNA) antibodies have a specificity of 97-100% for systemic lupus erythematosus (SLE) by immunofluorescence assay \[[@R6]\], they have also been reported in malignancies including colorectal adenocarcinoma \[[@R7]\]. Two cases of positive ANA and HOA have been reported in lung bronchial carcinoma and thymic carcinoma \[[@R8],[@R9]\]. However, this is the first report of positive anti-dsDNA antibodies associated with lung adenocarcinoma in a patient with HOA, a clinical and laboratory presentation which can be misdiagnosed as SLE.

CASE REPORT
===========

A 47 year-old African American female with a history of 15 pack-years of tobacco use and heavy alcohol use presented with an insidious onset of dry cough and progressive dyspnea over three months associated with swelling of the hands, wrists, elbows, knees, ankles, and feet for six months. She was evaluated for knee pain eight yearsearlier and x-ray showed bilateral osteonecrosis which was attributed to heavy alcohol use. ANA was positive but she denied alopecia, malar rash, dry eyes, dry mouth, parotid gland enlargement, Raynaud's phenomenon, photosensitive rashes, pleurisy, oral/nasal ulcers, and dark urine over the past eight years. She denied hemoptysis but reported a 10-pound weight loss over three months associated with fevers, dyspnea, chills, nausea, vomiting and inability to keep food down for two weeks.

On physical examination, the patient was thin, but with clubbing of all her fingers but not toes (Fig. **[1](#F1){ref-type="fig"}**). She was afebrile and did not have a malar rash, alopecia, or oral/nasal ulcers. On musculoskeletal examination, there were moderate knee effusions and mild warmth without overlying erythema. The proximal tibia and distal femur were exquisitely tender to palpation as was palpation of the distal tibia bilaterally. There were crackles in the left upper hemi-thorax. Her blood pressure was 131/85 mmHg, pulse was 83, and there were no heart murmurs or pericardial rubs. She did not have any neurological deficits.

Laboratory studies are summarized on Table **[1](#T1){ref-type="table"}**. The significant lab findings at admission were: hemoglobin 9.7 g/dl, hematocrit 29.6%, platelets 830,000/ml, erythrocyte sedimentation rate 111 mm/first hour, C-reactive protein 14.82 mg/dl, ANA positive by ELISA (Bio-Rad EIA kit), an extended ANA profile was positive for anti-dsDNA 170 IU/ML (Bio-rad EIA dilution 1:100), anti-SSA 204 AU/ML (Bio-rad EIA kit), and anti-SSB 123 (Bio-rad EIA kit). Complement C3 was 169 and complement C4 was 59. Urinalysis was negative for protein but positive for leukocyte esterase with 11-25 WBCs and 2-5 RBCs. Knee effusion was aspirated and the synovial fluid cell count was 232 white blood cells/microliter.

Chest x-rays showed left upper lobe opacity. Computed tomograpy of the chest showed a superior left upper lobe mass measuring 4.3 by 3.8 cm (Fig. **[2](#F2){ref-type="fig"}**). X-ray of the right leg showed cortical bone hypertrophy (periostitis) (Fig. **[3](#F3){ref-type="fig"}**). Biopsy of the left upper lobe mass led to the diagnosis of lung adenocarcinoma. Joint pain and swelling resolved by her follow up one month later after chemo-radiotherapy.

DISCUSSION
==========

Positive ANA has been detected in several malignancies and although anti-dsDNA antibodies are specific for the diagnosis of SLE in the correct clinical setting, there is growing evidence for its presence in several malignancies \[[@R7],[@R10]\]. The presence of autoantibodies in malignancy suggests a possible antibody dependent mechanism in eradicating the malignant cells as patients diagnosed with stage III non-small cell lung cancer (NSCLC) with positive ANAs had an improved survival compared to those who did not \[[@R11]\].

This case of HOA and lung adenocarcinoma with positive auto antiantibodies (ANA, anti-dsDNA, anti-SSA, and anti-SSB) can be misdiagnosed as SLE, especially in the presence of a joint effusion, chest pain, and dyspnea. Although the differential diagnoses for SLE is large, the clinician should consider HOA with associated malignancies when a patient presents with digital clubbing and non-inflammatory arthritis.

Our patient was also a smoker and tobacco use has been associated with positive anti-dsDNA antibodies and increased disease activity in SLE \[[@R12]\]. In a large cross-sectional study of healthy individuals, anti-dsDNA antibodies were not detected and ANA positivity could not be linked to either smoking or alcohol intake \[[@R13]\]. The increased cell death and deficient elimination of cellular debris may expose intracellular antigens to immune system and lead to autoantibody formation. In addition, the presence of autoantibodies in malignancy may represent an immune response important in eradicating the malignant cells \[[@R14]\].

In the context of extended history of tobacco use, positive antinuclear antibodies with positive anti-dsDNA antibodies, a thorough evaluation by a rheumatologist is essential for making proper diagnosis. We can conclude that patients who do not meet a diagnosis of an autoimmune connective tissue disease should be followed regularly and evaluated for alternative diagnoses including malignancy. In addition, age appropriate malignancy screening and low-dose computed tomography of the chest should be strongly considered \[[@R15]\].
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###### 

Selected laboratory results.

  Laboratory Test                   Results   Reference Range
  --------------------------------- --------- ------------------------
  Sodium-Serum                      136       132-144 mEq/L
  Potassium-Serum                   3.8       3.4-5.1 mEq/L
  Chloride-Serum                    94        101-111 mEq/L
  CO2 Content-Serum                 33        22-32 mEq/L
  Glucose                           126       70-125 mg/dL
  Urea Nitrogen-Serum               5         8-22 mg/dL
  Creatinine-Serum                  0.6        0.4-1.0 mg/dL
  Glomerular Filtration Rate Calc   \>60       \>60 mL/min/1.73 m\^2
  Osmo, Calculated                  271        275-300 mOsm/L
  Protein, Total-Serum              6.4       6.0-8.3 g/dL
  Albumin                           3.2       3.5-5.0 g/dL
  AST (SGOT)                        12        10-42 U/L
  ALT (SGPT)                        7         14-54 U/L
  WBC Count-Blood                   6.9       4.0-10.8 K/mcL
  RBC Count-Blood                   3.42       3.90-5.20 M/mcL
  Hemoglobin-Blood                  9.8       11.5-15.5 g/dL
  Hematocrit-Blood                  30.3      35.0-45.0 %
  RBC MCV                           89        80-97 fL
  RBC MCHC                          32.5      32.0-36.0 g/dL
  RBC RDW                           16.2      11.5-14.5 %
  Platelet Count-Blood              922       140-440 K/mcL
  \% Neutrophils-Blood              73        25-62 %
  \% Monocytes-Blood                8         2-11 %
  \% Lymphoctyes-Blood              17        20-53 %
  Complement C3                     169       87-200 mg/dl
  Complement C4                     59        19-52 mg/dL
  Anti-dsDNA                        172       0-120 AU/mL
  SSA                               204       0-120 AU/mL
  SSB                               123       0-120 AU/mL
  Smith                             14        0-120 AU/mL
  RNP                               16        0-120 AU/mL
  WBC Count-Synovial Fluid          232 (H)   0-10 /mcL
  RBC Count-Synovial Fluid          686       \-
